Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities
Net loss	$ (8,625,000)	$ (8,410,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	1,201,000	984,000
Common stock issued in lieu of salary to officers and fees for services from vendors	587,000	644,000
Common stock issued for interest	147,000	519,000
Interest expense related to amortization of the discount on convertible notes payable and line of credit and deferred financing costs	2,381,000	2,213,000
Interest expense related to the fair value of warrants issued as consent for variable debt	54,000
Debt conversion expense		276,000
Loss on extinguishment of debt	1,029,000	578,000
Bad debt expense		1,000
Deferred offering expense	13,000	19,000
Depreciation expense	48,000	36,000
Changes in assets and liabilities:
Accounts receivable	(72,000)	(19,000)
Inventories	7,000	8,000
Accounts payable and accrued expenses	88,000	143,000
Prepaid expenses and other current assets	(66,000)	(43,000)
Customer deposits	27,000
Net cash used in operating activities	(3,181,000)	(3,051,000)
Cash flows from investing activities
Leasehold improvements	(27,000)	(43,000)
Net cash used in investing activities	(27,000)	(43,000)
Cash flows from financing activities
Proceeds from convertible notes payable	4,335,000	880,000
Proceeds from conversion inducement		357,000
Proceeds from warrant exercise-price reduction		149,000
Proceeds from warrant exercise	380,000
Repayment of notes payable	(495,000)
Proceeds from line of credit		430,000
Net cash provided by financing activities	4,690,000	2,643,000
Net effect of foreign currency translation	(1,000)	(5,000)
Net change in cash	1,481,000	(456,000)
Cash at beginning of year	655,000	990,000
Cash at end of period	2,136,000	534,000
Supplemental disclosures of cash flow information
Interest	116,000	5,000
Income taxes	3,000	6,000
Non-cash investing and financing activities
Fair value of warrants issued with convertible notes	3,931,000	570,000
Right of use, operating lease and liability	341,000
Deemed dividend	781,000	297,000
Conversion of Convertible Notes Payable into Common Stock [Member]
Non-cash investing and financing activities
Conversion of debt	908,000	5,930,000
Conversion of Convertible Notes Issued with Original Issue Discount [Member]
Non-cash investing and financing activities
Conversion of debt	1,008,000	10,000
Conversion of Convertible Note Payable into Shares of Clyra [Member]
Non-cash investing and financing activities
Conversion of debt	440,000
Stock Issued for Exercise of Stock Options [Member]
Non-cash investing and financing activities
Fair value of stock issued		2,000
Stock Issued for Financing Fee [Member]
Non-cash investing and financing activities
Fair value of stock issued		85,000
Clyra Medical Common Stock [Member]
Cash flows from financing activities
Proceeds from the sale of stock	470,000
Lincoin Park Capital Stock [Member]
Cash flows from financing activities
Proceeds from the sale of stock		$ 827,000